Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $22.97, but opened at $23.86. Denali Therapeutics shares last traded at $23.20, with a volume of 48,081 shares trading hands.
Wall Street Analyst Weigh In
DNLI has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 target price on shares of Denali Therapeutics in a report on Thursday, November 7th. Jefferies Financial Group boosted their price target on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a report on Friday, November 1st. Bank of America increased their price target on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, September 4th. JPMorgan Chase & Co. dropped their price objective on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating for the company in a research report on Friday, October 11th. Finally, Raymond James reissued a "market perform" rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $40.40.
Read Our Latest Stock Report on DNLI
Denali Therapeutics Price Performance
The firm's fifty day moving average is $26.28 and its 200 day moving average is $24.85. The firm has a market capitalization of $3.35 billion, a price-to-earnings ratio of -8.49 and a beta of 1.35.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the previous year, the business earned ($0.72) EPS. Equities research analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.
Insider Activity at Denali Therapeutics
In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the firm's stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now owns 29,096 shares in the company, valued at approximately $844,656.88. This trade represents a 50.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ryan J. Watts sold 40,000 shares of the business's stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the transaction, the chief executive officer now directly owns 235,807 shares of the company's stock, valued at approximately $6,529,495.83. The trade was a 14.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 86,578 shares of company stock worth $2,474,440 over the last three months. Company insiders own 7.90% of the company's stock.
Institutional Investors Weigh In On Denali Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. CWM LLC increased its stake in Denali Therapeutics by 43.6% during the 3rd quarter. CWM LLC now owns 2,153 shares of the company's stock worth $63,000 after acquiring an additional 654 shares during the period. Quest Partners LLC bought a new stake in Denali Therapeutics during the third quarter worth $73,000. Assetmark Inc. boosted its holdings in shares of Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company's stock valued at $111,000 after purchasing an additional 580 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Denali Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock valued at $152,000 after purchasing an additional 920 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Denali Therapeutics during the 2nd quarter worth $194,000. Institutional investors and hedge funds own 92.92% of the company's stock.
About Denali Therapeutics
(
Get Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Further Reading
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
